Cambridge, UK and Indianapolis, US – 30 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 940,442 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels (“Admission”) to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. The New Ordinary Shares will rank pari passu in all respects with the Company’s existing Ordinary Shares in issue.
Following issue of the New Ordinary Shares, the Company’s total issued share capital consists of 54,888,198 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 54,888,198.
Acacia Pharma Group plc
Mile Bolinder, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571